DE69225757T2 - Lyophilische monoklonale antikörperpräparationen - Google Patents

Lyophilische monoklonale antikörperpräparationen

Info

Publication number
DE69225757T2
DE69225757T2 DE69225757T DE69225757T DE69225757T2 DE 69225757 T2 DE69225757 T2 DE 69225757T2 DE 69225757 T DE69225757 T DE 69225757T DE 69225757 T DE69225757 T DE 69225757T DE 69225757 T2 DE69225757 T2 DE 69225757T2
Authority
DE
Germany
Prior art keywords
lyophilic
monoclonal antibody
antibody preparations
preparations
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69225757T
Other languages
English (en)
Other versions
DE69225757D1 (de
Inventor
Tamotsu Fukuda
Yukio Shimazaki
Yasuyuki Kuroiwa
Shiro Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Chemicals Inc
Original Assignee
Mitsui Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69225757(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc
Application granted granted Critical
Publication of DE69225757D1 publication Critical patent/DE69225757D1/de
Publication of DE69225757T2 publication Critical patent/DE69225757T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69225757T 1991-03-08 1992-02-28 Lyophilische monoklonale antikörperpräparationen Expired - Fee Related DE69225757T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (fr) 1991-03-08 1992-02-28 Preparation lyophilisee d'anticorps monoclonaux

Publications (2)

Publication Number Publication Date
DE69225757D1 DE69225757D1 (de) 1998-07-09
DE69225757T2 true DE69225757T2 (de) 1998-12-03

Family

ID=12663510

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69225757T Expired - Fee Related DE69225757T2 (de) 1991-03-08 1992-02-28 Lyophilische monoklonale antikörperpräparationen
DE69232617T Expired - Fee Related DE69232617T2 (de) 1991-03-08 1992-02-28 Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69232617T Expired - Fee Related DE69232617T2 (de) 1991-03-08 1992-02-28 Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält

Country Status (10)

Country Link
US (1) US5908826A (de)
EP (2) EP0841067B1 (de)
JP (1) JPH0565233A (de)
AU (1) AU645187B2 (de)
CA (1) CA2082169A1 (de)
DE (2) DE69225757T2 (de)
DK (2) DK0841067T3 (de)
FI (1) FI924982A0 (de)
NO (1) NO924279L (de)
WO (1) WO1992015331A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
AU2228901A (en) * 1999-12-28 2001-07-09 Chugai Seiyaku Kabushiki Kaisha Stable antibody compositions and injection preparations
WO2002011753A1 (fr) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
EP2204190A1 (de) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM-Produktion durch umgewandelte Zellen und Verfahren zur Quantifizierung der IgM-Produktion
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
JP4671864B2 (ja) * 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
ES2553987T3 (es) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
EP1977763A4 (de) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antikörper-enthaltende stabilisierende zubereitung
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
ES2925992T3 (es) * 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
KR20090113340A (ko) * 2007-03-22 2009-10-29 임클론 엘엘씨 안정한 항체 제제
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
EA032189B9 (ru) 2010-03-01 2019-09-30 БАЙЕР ХЕЛЬСКЕР ЛЛСи Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
SG189138A1 (en) 2010-11-05 2013-05-31 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
PT2637690T (pt) 2010-11-11 2016-12-27 Abbvie Biotechnology Ltd Formulações líquidas de anticorpo anti-tnf-alfa de concentração elevada
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
JP6890602B2 (ja) 2015-11-06 2021-06-18 アセルタ ファーマ ビー．ブイ． ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
EP0327648B1 (de) * 1986-12-15 1993-06-09 MITSUI TOATSU CHEMICALS, Inc. Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten
DE3875852T2 (de) * 1987-08-10 1993-03-18 Miles Inc Gereinigtes igm.
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
WO1990011091A1 (en) * 1989-03-27 1990-10-04 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
EP0531539B1 (de) 1998-06-03
DE69225757D1 (de) 1998-07-09
DK0841067T3 (da) 2002-07-15
WO1992015331A1 (fr) 1992-09-17
AU645187B2 (en) 1994-01-06
NO924279D0 (no) 1992-11-06
DE69232617T2 (de) 2002-10-31
US5908826A (en) 1999-06-01
CA2082169A1 (en) 1992-09-09
EP0841067B1 (de) 2002-05-22
EP0531539A4 (de) 1995-04-05
EP0841067A1 (de) 1998-05-13
AU1337592A (en) 1992-10-06
NO924279L (no) 1992-11-06
DE69232617D1 (de) 2002-06-27
FI924982A (fi) 1992-11-04
EP0531539A1 (de) 1993-03-17
FI924982A0 (fi) 1992-11-04
DK0531539T3 (da) 1998-10-12
JPH0565233A (ja) 1993-03-19

Similar Documents

Publication Publication Date Title
DE69225757T2 (de) Lyophilische monoklonale antikörperpräparationen
DK666389A (da) Monoklonalt antistof
DE69232604D1 (de) Antikörperkonstrukte
DE68914244T2 (de) Monoklonaler Antikörper.
CY2006001I2 (el) Ανθρωποποιημενο heregulin αντισωμα
DK145493D0 (da) Antistof
DK19991D0 (da) Proteinpraeparationer
DK63187D0 (da) Krydsbeskyttende monoklonale antistofpraeparater
EP0580859A4 (en) Anti-eda monoclonal antibody
NO920523L (no) Ige-reseptor-antistoff
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
EP0506523A3 (en) Monoclonal antibodies
FI934588A (fi) Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
DK717888D0 (da) Monoklonale antistoffer
DK474189A (da) Monoklonalt antistof
NO890116D0 (no) Monoklonale antistoffer.
DK413389D0 (da) Monoklonale antistoffer
DE69023717T2 (de) Monoklonaler Antikörper.
DE68912772T2 (de) Monoklonaler antikörper gegen entero-viren.
DK370089A (da) Anti-urokinase monoklonale antistoffer
NO924803D0 (no) Tumor-relatert monoklonalt antistoff 88bv59
DE68916088T2 (de) Anti-CPBII-monoklonaler Antikörper.
DE69324928T2 (de) Monoklonaler antikörper
DK149591A (da) Proteinpraeparat
DK220688D0 (da) Monoklonalt antistof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MITSUI CHEMICALS, INC., TOKIO/TOKYO, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee